The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. At present it is unknown if these abnormalities develop in prediabetes and whether they contribute to the phenotypes observed. In this experiment we will use blockade of GLP1R to probe the contribution of endogenous GLP-1 secretion to the regulation of fasting glucose and islet function in prediabetes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 25
Maximum Age: 70
Healthy Volunteers: t
View:

• People with stable weight and no history of diabetes.

• Fasting glucose \< 126 mg/dL

• 2hr glucose after 75g OGTT \< 200 mg/dL

Locations
United States
Minnesota
Mayo Clinic in Rochester
RECRUITING
Rochester
Contact Information
Primary
Adrian Vella, MD
vella.adrian@mayo.edu
507-255-6515
Time Frame
Start Date: 2025-11-01
Estimated Completion Date: 2028-03-31
Participants
Target number of participants: 60
Treatments
Active_comparator: Exendin 9-39
Subjects will receive exendin 9-39 during the study
Placebo_comparator: Saline
Subjects will receive saline during the study
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic

This content was sourced from clinicaltrials.gov